DURHAM, N.C., OCTOBER 20, 2017 — Premier Research’s head of patient engagement will address patients’ emerging role in the development of novel drugs October 23 at the Cambridge Rare Disease Network Summit in Cambridge, U.K.
Juliet Moritz, the CRO’s Executive Director for Patient Engagement and Strategic Development, will discuss how patient advocacy groups are greatly expanding their role in drug development, a trend that has important implications for an industry targeting vast unmet needs in cancer and rare disease treatment.
Ms. Moritz will describe how the advocate role has grown beyond the traditional confines of fundraising and lobbying. Advocates today are involved in recruiting, study design, and even directly funding clinical trials — and industry is taking innovative steps to make the most of these relationships.
About Premier Research
Premier Research is a leading clinical development service provider that helps highly innovative biotech and specialty pharma companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatric, and rare disease. Premier Research operates in 84 countries and employs 1,100 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.